DiaMedica Announces Positive Final Results in Type 1 Diabetes Study
October 14 2010 - 11:46AM
Marketwired
DiaMedica Inc., (TSX VENTURE: DMA) is pleased to announce positive
final results from its previously announced type 1 diabetes study.
The study was designed to observe the potential protective
and/or regenerative effects on beta cells (cells from the pancreas
that produce insulin) in a widely accepted type 1 diabetes animal
model. DiaMedica, in consultation with Dr. Maureen Gannon at
Vanderbilt University, has confirmed that DM-99 can increase new
beta cells by 1,277% (p less than 0.01) when administered to
diseased animals compared to untreated diseased animals. Beta cell
proliferation induced by DM-99 trended to be even greater than
replication in non-diseased, untreated control animals.
The increased beta cell proliferation led to physiologically
important improvements in the diabetic state. Improvements included
the restoration of peak levels of plasma insulin to near normal
levels (p less than 0.05) with positive trends of increase in the
levels of both pancreatic and plasma insulin, which led to improved
blood glucose clearance in a oral glucose tolerance test with DM-99
treatment. On July 8th, DiaMedica reported initial results of the
study that included a 68% reduction in fasting blood glucose (p
less than 0.05) with DM-99.
"These results are very provocative and would indicate that this
compound offers both a level of protection of beta cells in a type
1 diabetes animal model as well as induces their proliferation,"
stated Dr. Maureen Gannon, Associate professor of Medicine at
Vanderbilt University, Division of Diabetes, Endocrinology and
Metabolism. "Having a therapeutic compound that can either protect
or proliferate beta cells is a key requirement for finding a cure
for type 1 diabetes so that therapies involved in replacing or
regenerating these cells can work long-term. DM-99 appears to be
able to perform both of these functions."
"The ability of DM-99 to significantly increase beta cell
replication combined with our earlier data showing the ability of
DM-99 to protect against a variety of autoimmune attacks may result
in a first in class treatment for type I diabetes", stated Mr. Rick
Pauls, President and CEO of DiaMedica. "We are currently developing
DM-199, a novel recombinant and humanized form of DM-99 for
commercialization."
About DiaMedica
DiaMedica is a biopharmaceutical company focused on developing
drugs with the potential to be broadly applicable in treating large
unmet diseases including diabetes, autoimmune disorders and
neurological diseases by protecting and proliferating a variety of
cells. Two of DiaMedica's products have demonstrated human efficacy
in lowering blood sugar levels in people diagnosed with Type 2
diabetes with an excellent safety profile. DiaMedica is listed on
the TSX Venture Exchange under the trading symbol "DMA".
Caution Regarding Forward-Looking Information
Certain statements contained in this press release constitute
forward-looking information within the meaning of applicable
Canadian provincial securities legislation (collectively, the
"forward-looking statements"). These forward-looking statements
relate to, among other things, DiaMedica's objectives, goals,
targets, strategies, intentions, plans, beliefs, estimates and
outlook, and can, in some cases, be identified by the use of words
such as "believe," "anticipate," "expect," "intend," "plan,"
"will," "may" and other similar expressions. In addition, any
statements that refer to expectations, projections or other
characterizations of future events or circumstances are
forward-looking statements. Specifically, this press release
contains forward-looking statements regarding matters such as, but
not limited to, the anticipated use of proceeds from the Offering,
management's assessment of DiaMedica's future plans, information
with respect to the advancement of DiaMedica's research and
development programs, and DiaMedica's other estimates and
expectations. These statements reflect management's current beliefs
and are based on information currently available to management.
Certain material factors or assumptions are applied in making
forward-looking statements, and actual results may differ
materially from those expressed or implied in such statements.
Important factors that could cause actual results to differ
materially from these expectations include, among other things:
uncertainties and risks related to our research and development
programs, the availability of additional financing, risks and
uncertainties relating to the anticipated use of proceeds, changes
in debt and equity markets, uncertainties related to clinical
trials and product development, rapid technological change,
uncertainties related to forecasts, competition, potential product
liability, additional financing requirements and access to capital,
unproven markets, the cost and supply of raw materials, management
of growth, effects of insurers' willingness to pay for products,
risks related to regulatory matters and risks related to
intellectual property matters.
Additional information about these factors and about the
material factors or assumptions underlying such forward-looking
statements may be found in the body of this news release, as well
as under the heading "Risk Factors" contained in DiaMedica's 2009
annual information form. DiaMedica cautions that the foregoing list
of important factors that may affect future results is not
exhaustive. When relying on DiaMedica's forward-looking statements
to make decisions with respect to DiaMedica, investors and others
should carefully consider the foregoing factors and other
uncertainties and potential events. Such forward-looking statements
are based on a number of estimates and assumptions, which may prove
to be incorrect, including, but not limited to, assumptions
regarding the availability of additional financing for research and
development companies, and general business and economic
conditions. These risks and uncertainties should be considered
carefully and investors and others should not place undue reliance
on the forward-looking statements. Although the forward-looking
statements contained in this press release are based upon what
management believes to be reasonable assumptions, DiaMedica cannot
provide assurance that actual results will be consistent with these
forward-looking statements. DiaMedica undertakes no obligation to
update or revise any forward-looking statement.
Contacts: DiaMedica Inc. Rick Pauls 204.477.7590 204.453.3745
(FAX) rpauls@diamedica.com
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024